Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.23 Insider Own5.30% Shs Outstand16.95M Perf Week3.84%
Market Cap12.94M Forward P/E- EPS next Y-0.71 Insider Trans-0.77% Shs Float16.05M Perf Month46.57%
Income-21.36M PEG- EPS next Q-0.16 Inst Own36.71% Short Float / Ratio4.68% / 3.54 Perf Quarter-12.11%
Sales0.62M P/S20.86 EPS this Y-120.28% Inst Trans2.89% Short Interest0.75M Perf Half Y-31.24%
Book/sh1.08 P/B0.71 EPS next Y38.36% ROA-37.07% Target Price4.62 Perf Year-62.03%
Cash/sh0.79 P/C0.97 EPS next 5Y- ROE-57.87% 52W Range0.43 - 2.78 Perf YTD-66.23%
Dividend- P/FCF- EPS past 5Y- ROI-116.70% 52W High-72.55% Beta0.50
Dividend %- Quick Ratio4.04 Sales past 5Y-3.04% Gross Margin-22.73% 52W Low79.58% ATR0.07
Employees19 Current Ratio4.04 Sales Q/Q-76.92% Oper. Margin-3214.15% RSI (14)62.09 Volatility7.64% 11.55%
OptionableYes Debt/Eq0.00 EPS Q/Q91.38% Profit Margin-3434.73% Rel Volume0.58 Prev Close0.82
ShortableYes LT Debt/Eq0.00 EarningsNov 08 AMC Payout0.00% Avg Volume212.41K Price0.76
Recom1.00 SMA2022.79% SMA5028.41% SMA200-10.37% Volume123,234 Change-7.49%
Date Action Analyst Rating Change Price Target Change
Jul-20-20Downgrade Credit Suisse Neutral → Underperform
Nov-11-19Downgrade Credit Suisse Outperform → Neutral $7 → $2
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Nov-09-23 11:06AM
Nov-08-23 05:22PM
Nov-07-23 04:05PM
Oct-26-23 04:30PM
08:30AM Loading…
Oct-03-23 08:30AM
Sep-12-23 01:02PM
Sep-06-23 08:30AM
Aug-22-23 05:30PM
Aug-13-23 05:33AM
Aug-11-23 06:07AM
Aug-10-23 05:30PM
Jul-27-23 04:05PM
08:00AM Loading…
Jul-21-23 08:00AM
Jul-18-23 08:00AM
May-10-23 06:25PM
May-04-23 10:00AM
May-03-23 10:00AM
Apr-27-23 04:05PM
Apr-05-23 08:30AM
Apr-04-23 12:30PM
Mar-30-23 06:15PM
Mar-29-23 10:13AM
Mar-21-23 04:05PM
Mar-14-23 08:30AM
08:30AM Loading…
Mar-01-23 08:30AM
Dec-29-22 06:02AM
Dec-27-22 08:30AM
Dec-19-22 08:17AM
Dec-08-22 08:30AM
Nov-17-22 05:17AM
Nov-14-22 05:15PM
Nov-03-22 08:30AM
Oct-31-22 08:30AM
Oct-27-22 08:30AM
Oct-26-22 08:30AM
Oct-25-22 04:42PM
Sep-06-22 04:30PM
Aug-25-22 08:30AM
Aug-11-22 05:35PM
Aug-10-22 08:30AM
Jul-28-22 04:50PM
Jul-08-22 06:28AM
May-20-22 12:49PM
May-19-22 11:56AM
May-16-22 08:45AM
May-12-22 05:35PM
May-10-22 05:35PM
May-09-22 07:30PM
Apr-27-22 08:00AM
Apr-25-22 08:30AM
Apr-21-22 08:30AM
Mar-31-22 04:10PM
Mar-29-22 01:08PM
Mar-10-22 05:15PM
Mar-03-22 04:05PM
Feb-01-22 08:30AM
Jan-31-22 04:24AM
Jan-27-22 01:38PM
Jan-12-22 08:30AM
Jan-10-22 08:30AM
Dec-23-21 08:05AM
Dec-15-21 08:30AM
Dec-01-21 07:12PM
Nov-23-21 05:09PM
Nov-15-21 06:45AM
Nov-10-21 08:30AM
Nov-02-21 06:22AM
Oct-28-21 03:06PM
Oct-21-21 09:32PM
Oct-04-21 07:30AM
Sep-10-21 03:19PM
Aug-30-21 05:10PM
Aug-26-21 08:30AM
Aug-19-21 07:07AM
Aug-16-21 05:25PM
Aug-12-21 04:01PM
Aug-09-21 04:30PM
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angotti Vincent J.Chief Executive OfficerSep 11Buy0.8010,0007,95091,805Sep 11 07:13 PM
Palmer Pamela PChief Medical OfficerAug 25Sale1.097,4428,10430,753Aug 25 04:45 PM
Palmer Pamela PChief Medical OfficerAug 24Sale1.179,51411,13138,195Aug 25 04:45 PM